0000899243-18-026069.txt : 20181003
0000899243-18-026069.hdr.sgml : 20181003
20181003171825
ACCESSION NUMBER: 0000899243-18-026069
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181001
FILED AS OF DATE: 20181003
DATE AS OF CHANGE: 20181003
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Loven Jakob
CENTRAL INDEX KEY: 0001753644
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38672
FILM NUMBER: 181105972
MAIL ADDRESS:
STREET 1: C/O ARVINAS, INC., 5 SCIENCE PARK
STREET 2: 395 WINCHESTER AVENUE
CITY: NEW HAVEN
STATE: CT
ZIP: 06511
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ARVINAS INC.
CENTRAL INDEX KEY: 0001655759
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 472566120
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 395 WINCHESTER COMPANY, LLC
STREET 2: 5 SCIENCE PARK
CITY: NEW HAVEN
STATE: CT
ZIP: 06511
BUSINESS PHONE: 203-535-1456
MAIL ADDRESS:
STREET 1: 395 WINCHESTER COMPANY, LLC
STREET 2: 5 SCIENCE PARK
CITY: NEW HAVEN
STATE: CT
ZIP: 06511
FORMER COMPANY:
FORMER CONFORMED NAME: ARVINAS HOLDING COMPANY, LLC
DATE OF NAME CHANGE: 20151015
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-10-01
0
0001655759
ARVINAS INC.
ARVN
0001753644
Loven Jakob
C/O ARVINAS, INC.
5 SCIENCE PARK, 395 WINCHESTER AVE.
NEW HAVEN
CT
06511
1
0
0
0
Common Stock
2018-10-01
4
P
0
312500
16.00
A
312500
I
See Footnote
Common Stock
2018-10-01
4
C
0
1381851
A
1694351
I
See Footnote
Series C Preferred Stock
2018-10-01
4
C
0
4491018
0.00
D
Common Stock
1381851
0
I
See Footnote
Reflects shares of the Issuer's Common Stock that were purchased in connection with the Issuer's initial public offering.
The shares are held directly by Nextech V Oncology S.C.S., SICAV-SIF. Nextech V GP S.a r.l. is the general partner of Nextech V Oncology S.C.S., SICAV-SIF. Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a member of the investment committee of Nextech Invest AG and may be deemed to have shared voting and/or investment power over the shares reported hereby. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
On October 1, 2018, the Series C Preferred Stock converted into Common Stock on a 3.25-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
/s/ Matthew Batters, as attorney-in-fact for Jakob Loven
2018-10-03